Literature DB >> 8426182

Circulating levels of soluble interleukin 2 receptors are elevated in the sera of humans with spinal cord injury.

J L Segal1, S R Brunnemann.   

Abstract

A unique molecular regulatory mechanism or final common molecular pathway mediating the autonomic dysfunction and several pathobiologic sequelae of spinal cord injury (SCI) in humans has not been delineated. Although seemingly disparate in etiopathogenesis, much of the pathology caused by traumatic disruption of the spinal cord may be attributable to the pleiotropism demonstrated by a unique family of endogenous bioactive molecules, the interleukins. To begin testing this hypothesis, we examined the sera of patients with chronic SCI for elevations in interleukin 1 beta (IL-1 beta) and interleukin 2 receptor (IL-2R) and compared them to a control population of able-bodied subjects. In comparison to control subjects, a statistically significant increase in IL-2R was observed in patients with cervical spinal myelopathy. Elevated levels of IL-2R were not seen in paraplegic patients. Significant differences between the means and variances of serum IL-1 beta could not be detected among the study groups. We conclude that the sera of quadriplegic patients with chronic SCI contain elevated levels of IL-2R and suggest that the elevated levels of IL-2R may be of diagnostic, prognostic, and therapeutic importance.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8426182     DOI: 10.1080/01952307.1993.11735881

Source DB:  PubMed          Journal:  J Am Paraplegia Soc        ISSN: 0195-2307


  2 in total

1.  Dermatological problems following spinal cord injury in Korean patients.

Authors:  Zee-A Han; Ja Young Choi; Young Jin Ko
Journal:  J Spinal Cord Med       Date:  2013-10-24       Impact factor: 1.985

Review 2.  Molecular diagnostics in neurotrauma: Are there reliable biomarkers and effective methods for their detection?

Authors:  Davran Sabirov; Sergei Ogurcov; Irina Baichurina; Nataliya Blatt; Albert Rizvanov; Yana Mukhamedshina
Journal:  Front Mol Biosci       Date:  2022-09-29
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.